KRAS and malignant colon neoplasm: The use of statistical tests to assess potential correlations between molecular parameters —specifically MMR/MSI status and KRAS gene mutational status— and the categories of CDX2 expression in colon cancer is hindered by inconsistencies in the evaluation of these biomarkers across all oncological stages.